regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-18 and is reviewed periodically as new material appears.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
=== Mechanism of action === Lisinopril is an ACE inhibitor, meaning it blocks the actions of angiotensin-converting enzyme (ACE) in the renin–angiotensin–aldosterone system (RAAS), preventing angiotensin I from being converted to angiotensin II. Angiotensin II is a potent direct vasoconstrictor and a stimulator of aldosterone release. Reduction in the amount of angiotensin II results in relaxation of the arterioles. Reduction in the amount of angiotensin II also reduces the release of aldosterone from the adrenal cortex, which allows the kidney to excrete sodium along with water into the urine and increases the retention of potassium ions. Specifically, this process occurs in the peritubular capillaries of the kidneys in response to a change in Starling forces. The inhibition of the RAAS system causes an overall decrease in blood pressure.
=== GPT === Generative pre-trained transformers (GPTs) are large language models (LLMs) that generate text based on the semantic relationships between words in sentences. Text-based GPT models are pre-trained on a large corpus of text that can be from the Internet. The pretraining consists of predicting the next token (a token being usually a word, subword, or punctuation). Throughout this pretraining, GPT models accumulate knowledge about the world and can then generate human-like text by repeatedly predicting the next token. Typically, a subsequent training phase makes the model more truthful, useful, and harmless, usually with a technique called reinforcement learning from human feedback (RLHF). Current GPT models are prone to generating falsehoods called "hallucinations". These can be reduced with RLHF and quality data, but the problem has been getting worse for reasoning systems. Such systems are used in chatbots, which allow people to ask a question or request a task in simple text. Current models and services include ChatGPT, Claude, Gemini, Copilot, and Meta AI. Multimodal GPT models can process different types of data (modalities) such as images, videos, sound, and text.
Evidence from the study of bone microanatomy of Neanderthal remains from Sesselfelsgrotte (Germany), indicative of an overall similar growth trajectory of Neanderthals and modern humans during their early life, is presented by Miszkiewicz et al. (2026), who also report the presence of probably pathological interglobular dentin in the studied fossil material that might be evidence of a metabolic bone disease. Zollikofer et al. (2026) compare the morphology of Neanderthal pelves from Sima de las Palomas (Spain) and Dederiyeh Cave (Syria) with those of modern humans, reporting evidence of morphological similarities of pelvic regions associated with childbirth, as well as evidence of differences in pelvic regions associated with locomotion. Sorrentino et al. (2026) report evidence of presence of overall more robust calcaneus in Neanderthals compared to modern humans, with the closest similarity to calcanei of highly mobile, unshod modern human groups. Verheijen et al. (2026) study evidence of Neanderthal activity in faunal remains from the Lehringen site (Germany), reporting evidence of defleshing of a straight-tusked elephant when its carcass was in fresh state and evidence of butchery of a beaver, bear and aurochs. Evidence indicating that exploitation of shellfish by Neanderthals occupying the Cave of Los Aviones (Spain) happened primarily during the colder months of the year is presented by García-Escárzaga et al. (2026).
Sources: en.wikipedia.org
=== Skin and hair conditions === Androgens such as testosterone and DHT play a critical role in the pathogenesis of a number of dermatological conditions including oily skin, acne, seborrhea, hirsutism (excessive facial/body hair growth in women), and male pattern hair loss (androgenic alopecia). In demonstration of this, women with complete androgen insensitivity syndrome do not produce sebum or develop acne and have little to no body, pubic, or axillary hair. Moreover, men with congenital 5α-reductase type II deficiency, 5α-reductase being an enzyme that greatly potentiates the androgenic effects of testosterone in the skin, have little to no acne, scanty facial hair, reduced body hair, and reportedly no incidence of male-pattern hair loss. Conversely, hyperandrogenism in women, for instance due to polycystic ovary syndrome or congenital adrenal hyperplasia, is commonly associated with acne and hirsutism, as well as virilization (masculinization) in general. In accordance with the preceding, antiandrogens are highly effective in the treatment of the aforementioned androgen-dependent skin and hair conditions. Because of the antiandrogenic activity of spironolactone, it can be quite effective in treating acne in women. In addition, spironolactone reduces oil that is naturally produced in the skin, so can be used to treat oily skin. Though not the primary intended purpose of the medication, the ability of spironolactone to be helpful with problematic skin and acne conditions was discovered to be one of the beneficial side effects and has been quite successful.
=== 10 May === Russian artillery struck Vovchansk in Kharkiv Oblast killing one person, according to Governor Oleh Syniehubov. Three others were injured in shelling across the region. The governors of Voronezh and Kursk Oblasts in Russia said that three drones were shot down by anti-aircraft defenses, with debris from one drone damaging a pipeline in Kursk. According to the Governor, Alexander Bogomaz, a Russian military enlistment office was damaged in Bryansk Oblast. An attack on a training ground in Voronezh Oblast wounded at least fourteen soldiers. Yoshimasa Hayashi, Minister for Foreign Affairs of Japan, announced that Japan was in talks with NATO to set up a NATO liaison office at Tokyo, citing the Russian invasion of Ukraine and its threat to global stability. According to him, the liaison office would send a message to nations near Japan that "Japan is engaging in a very steady manner with NATO". Czech President Petr Pavel, in a radio interview, offered the Aero L-159 ALCA to Ukraine, subject to a decision by the Czech government. They carry an array of western weapons that Ukrainian is already using and is also a descendant of the Aero L-39 Albatros that the Ukraine Air Force currently uses.
The epithelial–mesenchymal transition (EMT) is a process by which epithelial cells lose their cell polarity and cell–cell adhesion, and gain migratory and invasive properties to become mesenchymal stem cells; these are multipotent stromal cells that can differentiate into a variety of cell types. EMT is essential for numerous developmental processes including mesoderm formation and neural tube formation. EMT has also been shown to occur in wound healing, in organ fibrosis and in the initiation of metastasis in cancer progression. The inverse process is the mesenchymal-epithelial transition, a part of normal organ formation. Despite EMT generally being recognized as a common process, the resultant mesenchymal state is not known to be associated with any specific cellular characteristic or molecular markers that are valid across all EMT proceesses as of 2020. EMT cannot be accessed solely on the basis of molecular markers.
Sugar was first produced from sugar cane in the Indian subcontinent. Diverse species of sugar cane seem to have originated from India (Saccharum barberi and S. edule) and New Guinea (S. officinarum). Sugarcane is described in Chinese manuscripts dating to the 8th century BCE, which state that the use of sugarcane originated in India. Nearchus (admiral of Alexander the Great), the Greek physician Pedanius Dioscorides and the Roman Pliny the Elder also described sugar. In the mid-15th century, sugar was introduced into Madeira and the Canary Islands, where it was mass-produced. Christopher Columbus introduced it to the New World, leading to sugar industries in Cuba and Jamaica by the 1520s. The Portuguese took sugar cane to Brazil. Beet sugar, the starting point for the modern sugar industry, was a German invention. Beet sugar was first produced industrially in 1801 in Cunern, Prussia. Sugar became a household item by the 19th century, and this evolution of taste and demand for sugar as an essential food ingredient resulted in major economic and social changes. Demand drove, in part, the colonisation and industrialisation of previously under-developed lands. It was also intimately associated with slavery. World consumption increased more than 100 times from 1850 to 2000, led by the United Kingdom, where it increased from about 2 pounds per head per year in 1650 to 90 pounds by the early 20th century.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.